<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048680</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.460</org_study_id>
    <nct_id>NCT05048680</nct_id>
  </id_info>
  <brief_title>Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly</brief_title>
  <acronym>HYPOXAGE</acronym>
  <official_title>Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In line with the ever-growing aging of Western populations, the development of preventive&#xD;
      strategies to slow down the effects of aging on cardiovascular health represents a major&#xD;
      challenge in order to preserve functional capacities and a sufficient quality of life in the&#xD;
      elderly. The alteration of vascular function (at the cerebral and systemic level) with aging&#xD;
      is an important feature in the clinical picture including a decrease in physical and&#xD;
      cognitive capacities. Although physical activity is recognized as an essential means of&#xD;
      combating the effects of aging, optimizing its effects by defining the most effective&#xD;
      strategies of practice remains a key objective. Offering alternative interventions to&#xD;
      exercise training is also necessary for people who are unwilling or unable to engage in a&#xD;
      physical activity program. In this context, hypoxic conditioning, alone or in conjunction&#xD;
      with rehabilitative exercise training, is a new therapeutic modality with strong preclinical&#xD;
      validity, in particular from a cardiovascular standpoint, and used in other pathologies to&#xD;
      improve cardiovascular function and exercise performance and quality of life. Our aim is,&#xD;
      therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with&#xD;
      exercise training) on cerebrovascular health in the elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind (participant and research team) study in relation to the gas being delivered (normoxic or hypoxic mixture) during intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Middle cerebral artery flow velocity</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Changes in middle cerebral artery flow velocity in response to hypercapnia (5% CO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak oxygen uptake</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Peak oxygen uptake during a cardiopulmonary exercise test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Flow-mediated dilation in response to ischemia-reperfusion of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>24h blood pressure assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Sleep features assessed by polygraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Cognitive function assessed by the Montreal Cognitive Assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Before intervention; right after intervention; 2 months after intervention</time_frame>
    <description>Health-related quality of life assessed by the SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hypoxia</condition>
  <condition>Cerebral Hypoxia</condition>
  <condition>Brain Diseases</condition>
  <condition>Exercise</condition>
  <condition>Aging</condition>
  <condition>Cognitive Decline</condition>
  <condition>Healthy Aging</condition>
  <arm_group>
    <arm_group_label>Hypoxia - Rest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sessions of intermittent hypoxia at rest; 3 sessions/week; 8 weeks. To be compared with the placebo (normoxia) group at rest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxia - Rest</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sessions of normoxia at rest; 3 sessions/week; 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoxia - Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks. To be compared with the placebo (exercise under normoxia) group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxia - Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypoxia and/or Exercise</intervention_name>
    <description>Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.</description>
    <arm_group_label>Hypoxia - Exercise</arm_group_label>
    <arm_group_label>Hypoxia - Rest</arm_group_label>
    <arm_group_label>Normoxia - Exercise</arm_group_label>
    <arm_group_label>Normoxia - Rest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 to 80 years of age;&#xD;
&#xD;
          -  Being physically inactive (less than 150 min/week of moderate to intense physical&#xD;
             activity);&#xD;
&#xD;
          -  No chronic cardiovascular, respiratory, metabolic or neuromuscular disease&#xD;
             counterindicating an exercise training or hypoxic conditioning program;&#xD;
&#xD;
          -  Health coverage;&#xD;
&#xD;
          -  Being able to provide written fully informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body-mass index &gt;30 kg/m2;&#xD;
&#xD;
          -  Smoking (&gt; cigarettes/day);&#xD;
&#xD;
          -  Alcohol use (&gt; 10g/day);&#xD;
&#xD;
          -  Mental disorder or history of mental disorder;&#xD;
&#xD;
          -  Beta-blockade treatment;&#xD;
&#xD;
          -  Inability or refusal to provide informed consent;&#xD;
&#xD;
          -  No health coverage&#xD;
&#xD;
          -  People exceeding the annual ceiling of allowances received as a result of their&#xD;
             participation in other clinical trials;&#xD;
&#xD;
          -  People deprived of freedom by judicial or administrative decision;&#xD;
&#xD;
          -  People subject to legal protection, who cannot be included in clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Doutreleau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes, Grenoble Alpes University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane Doutreleau, MD, PhD</last_name>
    <phone>+33476767773</phone>
    <email>sdoutreleau@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel Vergès, PhD</last_name>
    <phone>+33476766860</phone>
    <email>sverges@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <state>Auvergne Rhône-Alpes</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Doutreleau, MD, PhD</last_name>
      <phone>+33476767773</phone>
      <email>sdoutreleau@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Samuel Vergès, PhD</last_name>
      <phone>+33476766860</phone>
      <email>sverges@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan at this point in time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

